Skip to main content
Erschienen in: Herz 4/2023

08.06.2023 | Main topic

Pulmonary hypertension associated with left heart disease

verfasst von: Max Wissmüller, Johannes Dohr, Joana Adler, Laurin Ochs, Tobias Tichelbäcker, Christopher Hohmann, Stephan Baldus, Stephan Rosenkranz, MD

Erschienen in: Herz | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Pulmonary hypertension (PH) is a common condition in patients with left heart disease (LHD) that is highly relevant for morbidity and mortality. While post-capillary in nature, the pathophysiology of PH in patients with LHD (heart failure/cardiomyopathy, valvular heart disease; other: congenital/acquired) is complex, and decisions about management strategies are challenging. Recently, the updated European Society of Cardiology/European Respiratory Society guidelines on the diagnosis and treatment of PH revisited hemodynamic definitions and the sub-classification of post-capillary PH, and provided numerous new recommendations on the diagnosis and management of PH associated with various types of LHD. Here, we review several novel aspects that focus on: (a) updated hemodynamic definitions, including the distinction between isolated post-capillary PH (IpcPH) and combined post- and pre-capillary PH (CpcPH); (b) the pathogenesis of PH-LHD, considering various components contributing to PH, such as pulmonary congestion, vasoconstriction, and vascular remodeling; (c) the prognostic relevance of PH and hemodynamic markers; (d) the diagnostic approach to PH-LHD; (e) management strategies in PH-LHD, distinguishing between targeting the underlying left heart condition, the pulmonary circulation, and/or impaired right ventricular function. In conclusion, precise clinical and hemodynamic characterization and detailed phenotyping are essential for prognostication and the management of patients with PH-LHD.
Literatur
1.
Zurück zum Zitat Humbert M, Kovacs G, Hoeper MM et al (2022) 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43:3618–3731PubMedCrossRef Humbert M, Kovacs G, Hoeper MM et al (2022) 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43:3618–3731PubMedCrossRef
2.
Zurück zum Zitat Rosenkranz S, Gibbs JSR, Wachter R et al (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37:942–954PubMedCrossRef Rosenkranz S, Gibbs JSR, Wachter R et al (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37:942–954PubMedCrossRef
3.
Zurück zum Zitat Guazzi M, Naeije R (2017) Pulmonary hypertension in heart failure: pathophysiology, pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 69:1718–1734PubMedCrossRef Guazzi M, Naeije R (2017) Pulmonary hypertension in heart failure: pathophysiology, pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 69:1718–1734PubMedCrossRef
5.
Zurück zum Zitat Obokata M, Reddy YNV, Melenovsky V et al (2019) Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 40:689–697PubMedCrossRef Obokata M, Reddy YNV, Melenovsky V et al (2019) Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 40:689–697PubMedCrossRef
6.
Zurück zum Zitat Melenovsky V, Hwang SJ, Lin G et al (2014) Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 35:3452–3462PubMedPubMedCentralCrossRef Melenovsky V, Hwang SJ, Lin G et al (2014) Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 35:3452–3462PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Omote K, Sorimachi H, Obokata M et al (2022) Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. Eur Heart J 43:3417–3431PubMedPubMedCentralCrossRef Omote K, Sorimachi H, Obokata M et al (2022) Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. Eur Heart J 43:3417–3431PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Tichelbäcker T, Dumitrescu D, Gerhardt F et al (2019) Pulmonary hypertension and valvular heart disease. Herz 44:491–501PubMedCrossRef Tichelbäcker T, Dumitrescu D, Gerhardt F et al (2019) Pulmonary hypertension and valvular heart disease. Herz 44:491–501PubMedCrossRef
9.
Zurück zum Zitat Maron BA, Hess E, Maddox TM et al (2016) Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation 133:1240–1248PubMedPubMedCentralCrossRef Maron BA, Hess E, Maddox TM et al (2016) Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation 133:1240–1248PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Douschan P, Kovacs G, Avian A et al (2018) Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care Med 197:509–516PubMedCrossRef Douschan P, Kovacs G, Avian A et al (2018) Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care Med 197:509–516PubMedCrossRef
11.
Zurück zum Zitat Kolte D, Lakshmanan S, Jankowich MD et al (2018) Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J Am Heart Assoc 7:e9729PubMedPubMedCentralCrossRef Kolte D, Lakshmanan S, Jankowich MD et al (2018) Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J Am Heart Assoc 7:e9729PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Maron BA, Brittain EL, Hess E et al (2020) Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 8:873–884PubMedPubMedCentralCrossRef Maron BA, Brittain EL, Hess E et al (2020) Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 8:873–884PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Vanderpool RR, Saul M, Nouraie M et al (2018) Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol 3:298–306PubMedPubMedCentralCrossRef Vanderpool RR, Saul M, Nouraie M et al (2018) Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol 3:298–306PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Palazzini M, Dardi F, Manes A et al (2018) Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes. Eur J Heart Fail 20:248–255PubMedCrossRef Palazzini M, Dardi F, Manes A et al (2018) Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes. Eur J Heart Fail 20:248–255PubMedCrossRef
15.
Zurück zum Zitat Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM (2020) Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation 141:678–693PubMedCrossRef Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM (2020) Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation 141:678–693PubMedCrossRef
16.
Zurück zum Zitat Tello K, Wan J, Dalmer A et al (2019) Validation of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension. Circ Cardiovasc Imaging 12:e9047PubMedPubMedCentralCrossRef Tello K, Wan J, Dalmer A et al (2019) Validation of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension. Circ Cardiovasc Imaging 12:e9047PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Fauvel C, Raitiere O, Boucly A et al (2022) Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. J Heart Lung Transplant 41:1761–1772PubMedCrossRef Fauvel C, Raitiere O, Boucly A et al (2022) Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. J Heart Lung Transplant 41:1761–1772PubMedCrossRef
18.
Zurück zum Zitat Guazzi M, Dixon D, Labate V et al (2017) RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes. JACC Cardiovasc Imaging 10:1211–1221PubMedCrossRef Guazzi M, Dixon D, Labate V et al (2017) RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes. JACC Cardiovasc Imaging 10:1211–1221PubMedCrossRef
19.
Zurück zum Zitat Huston JH, Maron BA, French J et al (2019) Association of mild echocardiographic pulmonary hypertension with mortality and right ventricular function. JAMA Cardiol 4:1112–1121PubMedPubMedCentralCrossRef Huston JH, Maron BA, French J et al (2019) Association of mild echocardiographic pulmonary hypertension with mortality and right ventricular function. JAMA Cardiol 4:1112–1121PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726PubMedCrossRef McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726PubMedCrossRef
21.
Zurück zum Zitat Vahanian A, Beyersdorf F, Praz F et al (2022) 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 43:561–632PubMedCrossRef Vahanian A, Beyersdorf F, Praz F et al (2022) 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 43:561–632PubMedCrossRef
22.
Zurück zum Zitat Gaemperli O, Moccetti M, Surder D et al (2012) Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 98:126–132PubMedCrossRef Gaemperli O, Moccetti M, Surder D et al (2012) Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 98:126–132PubMedCrossRef
23.
Zurück zum Zitat Tigges E, Blankenberg S, von Bardeleben RS et al (2018) Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 20:585–594PubMedCrossRef Tigges E, Blankenberg S, von Bardeleben RS et al (2018) Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 20:585–594PubMedCrossRef
24.
Zurück zum Zitat O’Sullivan CJ, Wenaweser P, Ceylan O et al (2015) Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 8:e2358PubMedCrossRef O’Sullivan CJ, Wenaweser P, Ceylan O et al (2015) Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 8:e2358PubMedCrossRef
25.
Zurück zum Zitat Bermejo J, González-Mansilla A, Mombiela T et al (2021) Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival. J Am Heart Assoc 10(2):e19949PubMedPubMedCentralCrossRef Bermejo J, González-Mansilla A, Mombiela T et al (2021) Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival. J Am Heart Assoc 10(2):e19949PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Bermejo J, Yotti R, García-Orta R et al (2018) Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 39:1255–1264PubMedCrossRef Bermejo J, Yotti R, García-Orta R et al (2018) Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 39:1255–1264PubMedCrossRef
27.
Zurück zum Zitat Abraham WT, Perl L (2017) Implantable hemodynamic monitoring for heart failure patients. J Am Coll Cardiol 70:389–398PubMedCrossRef Abraham WT, Perl L (2017) Implantable hemodynamic monitoring for heart failure patients. J Am Coll Cardiol 70:389–398PubMedCrossRef
28.
Zurück zum Zitat Abraham WT, Stevenson LW, Bourge RC et al (2016) Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 387:453–461PubMedCrossRef Abraham WT, Stevenson LW, Bourge RC et al (2016) Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 387:453–461PubMedCrossRef
29.
Zurück zum Zitat Lindenfeld J, Zile MR, Desai AS et al (2021) Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 398:991–1001PubMedCrossRef Lindenfeld J, Zile MR, Desai AS et al (2021) Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 398:991–1001PubMedCrossRef
30.
Zurück zum Zitat Shavelle DM, Desai AS, Abraham WT et al (2020) Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS post-approval study. Circ Heart Fail 13(8):e6863PubMedPubMedCentralCrossRef Shavelle DM, Desai AS, Abraham WT et al (2020) Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS post-approval study. Circ Heart Fail 13(8):e6863PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Angermann C, Assmus B, Anker SD et al (2020) Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European monitoring study for heart failure (MEMS-HF). Eur J Heart Fail 22:1891–1901PubMedCrossRef Angermann C, Assmus B, Anker SD et al (2020) Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European monitoring study for heart failure (MEMS-HF). Eur J Heart Fail 22:1891–1901PubMedCrossRef
32.
Zurück zum Zitat Aßmus B, Angermann CE, Alkhlout B et al (2022) Treatment response to heart failure management guided by remote pulmonary-artery-pressure-monitoring depends on presence and severity of pulmonary hypertension. Eur J Heart Fail 24:2320–2330PubMed Aßmus B, Angermann CE, Alkhlout B et al (2022) Treatment response to heart failure management guided by remote pulmonary-artery-pressure-monitoring depends on presence and severity of pulmonary hypertension. Eur J Heart Fail 24:2320–2330PubMed
33.
Zurück zum Zitat Tran JS, Havakuk O, McLeod JM et al (2021) Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail 8:1706–1710PubMedPubMedCentralCrossRef Tran JS, Havakuk O, McLeod JM et al (2021) Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail 8:1706–1710PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Codina P, Domingo M, Barceló E et al (2022) Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Fail 9:2170–2180PubMedPubMedCentralCrossRef Codina P, Domingo M, Barceló E et al (2022) Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Fail 9:2170–2180PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Mullens W, Martens P, Forouzan O et al (2020) Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring. ESC Heart Fail 7:2071–2073PubMedPubMedCentralCrossRef Mullens W, Martens P, Forouzan O et al (2020) Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring. ESC Heart Fail 7:2071–2073PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Nassif ME, Qintar M, Windsor SL et al (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation 143:1673–1686PubMedCrossRef Nassif ME, Qintar M, Windsor SL et al (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation 143:1673–1686PubMedCrossRef
37.
Zurück zum Zitat Packer M, McMurray JJV, Krum H et al (2017) Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. JACC Heart Fail 5:317–326PubMedCrossRef Packer M, McMurray JJV, Krum H et al (2017) Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. JACC Heart Fail 5:317–326PubMedCrossRef
38.
Zurück zum Zitat Vachiery JL, Delcroix M, Al-Hiti H et al (2018) Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 51:1701886PubMedCrossRef Vachiery JL, Delcroix M, Al-Hiti H et al (2018) Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 51:1701886PubMedCrossRef
39.
Zurück zum Zitat the SERENADE Investigators, Shah SJ, Bonderman D, Borlaug BA et al A study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction and pulmonary vascular disease (SERENADE). Presented at HFA Heart Failure 2022, Madrid (Abstract) the SERENADE Investigators, Shah SJ, Bonderman D, Borlaug BA et al A study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction and pulmonary vascular disease (SERENADE). Presented at HFA Heart Failure 2022, Madrid (Abstract)
40.
Zurück zum Zitat Califf RM, Adams KF, McKenna WJ et al (1997) A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan international randomized survival trial (FIRST). Am Heart J 134:44–54PubMedCrossRef Califf RM, Adams KF, McKenna WJ et al (1997) A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan international randomized survival trial (FIRST). Am Heart J 134:44–54PubMedCrossRef
41.
Zurück zum Zitat Rosenkranz S, Lang IM, Blind R et al (2018) Pulmonary hypertension associated with left heart disease: updated recommendations of the Cologne consensus conference 2018. Int J Cardiol 272S:53–62PubMedCrossRef Rosenkranz S, Lang IM, Blind R et al (2018) Pulmonary hypertension associated with left heart disease: updated recommendations of the Cologne consensus conference 2018. Int J Cardiol 272S:53–62PubMedCrossRef
42.
Zurück zum Zitat Cooper TJ, Cleland JGF, Guazzi M et al (2022) Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial. Eur J Heart Fail 24:1239–1248PubMedCrossRef Cooper TJ, Cleland JGF, Guazzi M et al (2022) Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial. Eur J Heart Fail 24:1239–1248PubMedCrossRef
43.
Zurück zum Zitat Hoendermis E, Liu LCY, Hummel YM et al (2015) Effects of sildenafil on invasive hemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36:2565–2573PubMedCrossRef Hoendermis E, Liu LCY, Hummel YM et al (2015) Effects of sildenafil on invasive hemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36:2565–2573PubMedCrossRef
44.
Zurück zum Zitat Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase‑5 inhibition in a 1-year study. Circulation 124:164–174PubMedCrossRef Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase‑5 inhibition in a 1-year study. Circulation 124:164–174PubMedCrossRef
45.
Zurück zum Zitat Opitz CF, Hoeper MM, Gibbs JS et al (2016) Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 68:368–378PubMedCrossRef Opitz CF, Hoeper MM, Gibbs JS et al (2016) Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 68:368–378PubMedCrossRef
46.
Zurück zum Zitat Kramer T, Dumitrescu D, Gerhardt F et al (2019) Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int J Cardiol 283:152–158PubMedCrossRef Kramer T, Dumitrescu D, Gerhardt F et al (2019) Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int J Cardiol 283:152–158PubMedCrossRef
47.
Zurück zum Zitat SOCRATES-REDUCED Investigators, Gheorghiade M, Greene SJ, Butler J et al (2015) Effect of Vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA 314:2251–2262CrossRef SOCRATES-REDUCED Investigators, Gheorghiade M, Greene SJ, Butler J et al (2015) Effect of Vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA 314:2251–2262CrossRef
48.
Zurück zum Zitat Pieske B, Maggioni AP, Lam CSP et al (2017) Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 38:1119–1127PubMedPubMedCentralCrossRef Pieske B, Maggioni AP, Lam CSP et al (2017) Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 38:1119–1127PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Filippatos G, Maggioni AP, Lam CSP et al (2017) Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail 19:782–791PubMedCrossRef Filippatos G, Maggioni AP, Lam CSP et al (2017) Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail 19:782–791PubMedCrossRef
50.
Zurück zum Zitat Armstrong PW, Pieske B, Anstrom KJ et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883–1893PubMedCrossRef Armstrong PW, Pieske B, Anstrom KJ et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883–1893PubMedCrossRef
51.
Zurück zum Zitat Bonderman D, Ghio S, Felix SB et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502–511PubMedCrossRef Bonderman D, Ghio S, Felix SB et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502–511PubMedCrossRef
52.
Zurück zum Zitat Dachs TM, Duca F, Rettl R et al (2022) Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. Eur Heart J 43:3402–3413PubMedPubMedCentralCrossRef Dachs TM, Duca F, Rettl R et al (2022) Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. Eur Heart J 43:3402–3413PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Hoeper MM, Badesch DB, Ghofrani HA et al (2023) A phase 3 trial of Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 388:1478–1490PubMedCrossRef Hoeper MM, Badesch DB, Ghofrani HA et al (2023) A phase 3 trial of Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 388:1478–1490PubMedCrossRef
Metadaten
Titel
Pulmonary hypertension associated with left heart disease
verfasst von
Max Wissmüller
Johannes Dohr
Joana Adler
Laurin Ochs
Tobias Tichelbäcker
Christopher Hohmann
Stephan Baldus
Stephan Rosenkranz, MD
Publikationsdatum
08.06.2023
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 4/2023
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-023-05189-z

Weitere Artikel der Ausgabe 4/2023

Herz 4/2023 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.